Introduction
gastrointestinal or gynecologic primary tumors, peritoneal cancer, Peritoneal cancer, CRS, mesothelioma
METASTASIS, PERITONEAL CANCER, PERITONEAL CANCER, MESOTHELIOMA, REGRESSION
Peritoneal cancer primarily occurs as mesothelioma or metastasis of mainly gastrointestinal or gynecologic primary tumors (Henderson et al. The standard therapy depends on the therapeutic intention. If it is curative, sCHT and/ CRS with HIPEC are considered. In a palliative situation, sCHT and a purely symptom-oriented “watch and wait” strategy are practicable options. The treatment decision depends on the peritoneal cancer index (PCI) according to Sugarbaker (Harmon and Sugarbaker PIPAC is a relatively new palliative treatment option for clearly defined patients with PSMs, usually in combination with sCHT (Solaß et al. Previously, our group has described the surgical technique and safety aspects regarding the patient as well as surgical staff (Gockel et al. Although sCHT is still the gold standard in treating PSMs, it is believed to have little effect because of the limited drug delivery into the peritoneal surface (Minchinton and Tannock However, the role which PIPAC plays in PSM treatment is still poorly defined. Presently, there are no prospective long-term data on PIPAC’s effects on prognosis and histopathologic regression (Grass et al. Therefore, in November 2015, we initiated a monocentric registry study (NCT03100708) to prospectively assess patients’ safety in conjunction with perioperative morbidity and mortality, feasibility and effectiveness, prognostic effect, and impact on quality of life.